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Abstract
Background: Dexmedetomidine is a potent a2-adrenergic agonist U.S. Food and Drug Administration (FDA)
approved for sedation. While its use as an analgesic has been described in the palliative medicine literature, its
use for managing an acute neuropathic pain episode is less well known.
Methods: Here we describe the use of adjuvant dexmedetomidine in a patient with metastatic sarcoma suffering
from an acute postoperative neuropathic pain crisis.
Conclusion: Among patients with acute neuropathic pain for whom additional opioids raises respiratory-related
concerns, the use of dexmedetomidine should be considered as a viable treatment alternative.
Introduction
Dexmedetomidine (Precedex, Hospira, Lake Forest,IL) is an a2-adrenergic agonist approved by the U.S.
Food and Drug Administration (FDA) for sedation.1 Its un-
ique mechanism of action allows it to be used in combination
with opioids and benzodiazepines without concern for con-
tributing to respiratory depression.1 In the palliative care
literature, dexmedetomidine has been shown to benefit pa-
tients because it allows for interactive sedation at the end of
life.2 Additional uses include treatment for complex regional
pain syndrome,3 opioid-induced hyperalgesia,4 and intracta-
ble cancer pain.5 Although evidence shows that a2-agonists
such as clonidine and dexmedetomidine can be helpful for
acute pain management, they are less commonly used for this
purpose.6 In this case study we discuss the use of dexmede-
tomidine in a patient on concurrent methadone therapy who
experienced a postoperative neuropathic pain crisis unre-
sponsive to high-dose opioids.
Case Description
G.B. is a 75-year-old man with a history of undifferenti-
ated sarcoma of the left patella who was referred to the pal-
liative care clinic by his primary care provider for treatment
of longstanding nonmalignant back and knee pain related to
his sarcoma. Over the previous year his primary care provider
prescribed multiple opioid and nonopioid medications. G.B.
was hospitalized in June 2011 for pain crisis of his left knee
and was started on morphine patient-controlled analgesia
(PCA). After dose finding, he was subsequently discharged
on long-acting morphine, 60mg twice daily, and morphine
immediate release (IR), 15mg daily. He was seen in follow-
up in the palliative medicine clinic. At that time, due to on-
going pain, his long-acting morphine was increased to three
times daily and morphine IR increased to 15–30mg four
times per day as needed. A week later the patient called the
clinic complaining of increasing pain, and long-acting mor-
phine was increased to 120mg twice per day and morphine
IR was increased to 30–45mg four times per day as needed.
Three days later he called from home due to a pain crisis, fall,
memory problems, hallucinations, and drowsiness. He was
advised to go to the emergency department for further
evaluation. Upon admission, palliative care consultants re-
commended rotation to methadone, 15mg orally, three times
per day as needed, via the Morley-Makin protocol.7 Three
days after discharge via phone visit, the patient reported that
his pain was significantly improved and he was not experi-
encing any side effects. His methadone dosing schedule was
30mg orally every 8 hours, with 15mg orally every 4 hours
as needed. Later that same day, the patient’s son called to
report that his father appeared somnolent, and methadone
was decreased to 25mg orally every 8 hours and 10mg orally
every 4 hours as needed.
Two days later G.B. was admitted to the hospital for a
planned resection of sarcoma and lymph node dissection. His
postoperative pain management course was complicated by a
pain crisis that proved unresponsive to 400lg fentanyl intra-
venous push, 10mg intravenous morphine, 2mg intravenous
midazolam, and 35mgmethadone taken orally. Palliative care
was consulted and the patient was admitted to the surgical
intensive care unit (ICU) for fentanyl infusion, in addition to
his oral methadone regimen. He responded well to 150lg/hr
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infusion of fentanyl. Repeat operation and wound closure 1
week later had an uncomplicated postoperative course.
During recovery G.B. continued on methadone 30mg or-
ally every 8 hours and 10mg orally every 4 hours as needed.
His postoperative course, from the wound closure, was fur-
ther complicated by poor wound healing requiring operative
debridement 15 days after his initial resection. At that time,
postoperative pain was managed with fentanyl infusion in the
medical ICU. G.B. continued to have difficulty with wound
healing, and required left above-the-knee amputation 14 days
after debridement.
The palliative care team was paged to the postanesthesia
care unit to address a pain crisis, where G.B. rated his pain at
‘‘10 out of 10,’’ describing it as ‘‘squeezing’’ and ‘‘vise-like’’
over his left leg. He had his eyes closed and was writhing on
the bed during the examination. This pain was unresponsive
to fentanyl infusion titrated to 350 lg/hr. Despite his nothing-
by-mouth (NPO) status, he had not missed any methadone
doses prior to his going to the operating room.
For G.B.’s refractory pain crisis, we recommended dex-
medetomidine with a bolus of 0.5 lg/kg given over 20 min-
utes then 0.2 lg/kg per hour with the recommendation to
increase by 0.2 lg/kg per hour every 30–60 minutes and ti-
trate to analgesia, with a maximum dose of 1.5 lg/kg per
hour. Overnight the dexmedetomidine was kept at 0.2 lg/hr
and the fentanyl was reduced to 50 lg/hr. The following day
he reported his left leg pain at 8 of 10 but significantly im-
proved. When seen on rounds he was able to speak and eat
lunch. On postoperative day 2 he was weaned off both the
fentanyl and dexmedetomidine infusions. Throughout his
postoperative course he remained on methadone at previous
dose of 30mg orally every 8 hours and 10mg orally every 4
hours as needed. Methadone was slowly decreased over the
next few weeks due to decreased pain.
Discussion
Much of the literature describing the clinical application of
dexmedetomidine emphasizes either its role in perioperative
and intensive care sedation or its use in the management of
routine postoperative pain as an opioid-sparing agent.8,9 This
case study demonstrates the role that adjuvant dexmedeto-
midine can have in the management of an acute neuropathic
pain crisis.
Despite high-dose fentanyl infusion while on concurrent
methadone therapy for chronic pain, our patient had no sig-
nificant relief of his postoperative suffering. G.B.’s postop-
erative consult with the palliative care team revealed he not
only suffered from somatic postsurgical pain but also likely
neuropathic phantom limb pain. The teamwas concerned that
further titration of opioids or the addition of benzodiazepines
could lead to respiratory depression—as experienced after a
prior operation—hence warranting an agent with an alter-
native mechanism of action. Treatments such as ketamine
and regional anesthesia were considered. However, because
G.B. was already on methadone the effect of ketamine and its
action on the N-methyl-d-aspartate receptor was likely to be
minimal, and regional anesthesia was logistically unwork-
able due to staffing constraints and supply-related limitations.
Soon after the infusion of dexmedetomidine, G.B. not only
obtained relief from his acute pain, he was able to get much
needed rest. In sharp contrast to the previous evening, the
morning after infusion he was able to eat and interact without
concern for his pain. This rapid onset of pain relief makes
dexmedetomidine an ideal agent for use during an acute
neuropathic pain crisis. Similar to findings reported by Ro-
berts et al.5 where dexmedetomidine was used to treat in-
tractable cancer pain, G.B. was able to further taper the dose
of methadone while maintaining good pain control. This
suggests that patients using dexmedetomidine may benefit
from its opioid dose-sparing effect, thereby limiting opioid-
related side effects. Importantly, while dexmedetomidine is a
commonly used sedative, G.B. experienced neither excessive
sedation nor somnolence while receiving the infusion, en-
abling him to actively participate in his own pain-management
plan by accurately reporting his pain to the care team.
In addition to limiting opioid-related side effects, GB
benefited from dexmedetomidine’s relatively quick onset of
action compared to agents more typically associated with the
treatment of neuropathic pain. In this case, dexmedetomidine
provided immediate relief of acute neuropathic pain that had
been unresponsive to oral methadone and a high-dose fen-
tanyl infusion.When considered in light of findings described
by Nama et al.,3 in which dexmedetomidine effectively re-
lieved acute pain associated with complex regional pain
syndrome, findings from this case underscore the utility
dexmedetomidine may have in treating a number of refrac-
tory neuropathic pain syndromes.
Although dexmedetomidine is generally safe and well
tolerated, cardiac side effects such as hypotension, brady-
cardia, and atrial fibrillation have been noted;1 however, an
infusion rate of 0.2 lg/kg per hour was easily tolerated de-
spite G.B.’s history of coronary artery disease.
While dexmedetomidine can be extremely effective in the
management of an acute pain crisis, both its cost and a lack of
familiarity or comfort with its use could be limiting in some
settings. Likewise, because dexmedetomidine is not com-
monly used outside of operating rooms and postanesthesia care
units, some clinicians may not feel comfortable with its use.
Before using dexmedetomidine to treat acute pain, palliative
care clinicians may need to establish unit-specific procedures,
administration guidelines, and provide staff education.
Conclusion
Our patient, a 75-year-old man with metastatic sarcoma
suffering from an acute episode of refractory postoperative
neuropathic pain, experienced relief with the addition of
dexmedetomidine to his medication regimen. This case fur-
ther demonstrates the role that dexmedetomidine can play in
the management of an acute pain crisis. Our patient not only
experienced rapid relief from his pain—within hours of
starting the dexmedetomidine infusion—there were neither
reported nor observed side effects related to the therapy.
While this case describes dexmedetomidine as a useful ad-
junct to traditional opioid medications, the relative absence
of literature on the topic suggests dexmedetomidine may be
underutilized in the palliative care setting. Among patients
with acute neuropathic pain for whom additional opioids
raises respiratory-related concerns, and the severity of pain
requires an agent with a relatively rapid onset of action to
control the neuropathic component of pain, the use of dex-
medetomidine should be considered as a viable treatment
alternative.
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